GRAIL Shareholders Face August Deadline in Securities Fraud Lawsuit

The lawsuit, filed by Hagens Berman Sobol Shapiro LLP, centers on claims that GRAIL executives misled the market between May 13, 2025, and February 19, 2026. According to the complaint, the company touted a three-year follow-up period as sufficient to prove the efficacy of its screening technology in reducing late-stage cancer diagnoses. Plaintiffs allege that leadership ignored internal data suggesting this timeline was insufficient while selectively releasing favorable top-line results to inflate share prices.

The facade crumbled on February 19, 2026, when GRAIL disclosed that the NHS-Galleri trial failed to meet its primary endpoint. The company conceded that a longer follow-up period was likely required, triggering a massive sell-off. GRAL shares plummeted 50.55% the following day, dropping from $101.53 to $50.21 and wiping out more than $2.2 billion in market value.

Reed Kathrein, the Hagens Berman partner heading the investigation, is now scrutinizing exactly when management realized the three-year study design was flawed. Beyond the class action, the firm is encouraging potential whistleblowers with non-public information to come forward, citing the possibility of SEC-backed rewards for original information that aids in recovery efforts.